LAMTOR5

Across TCGA pan-cancer cohorts, LAMTOR5 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LAMTOR5 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher LAMTOR5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LAMTOR5 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LUSC and BLCA are the cancer types where LAMTOR5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.168	0.675	.021	18	view →
BLCA	OS	Median	IV	0.506	0.285	.001	10	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LAMTOR5–LUSC (OS)

Open the LUSC breakdown →